All In MedTech

Device Trial Radar · NCT06779630

Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

A Prospective Multicenter Single Arm Study to Assess the Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus-Eluting Coronary Stent System for the Treatment of Subjects With Atherosclerotic Lesion(s)

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Jul 18, 2025

Primary completion

Sep 2027

Study completion Sep 2031

Sponsor

Lead sponsor
TeleflexPublic (TFX)
Sponsor type
Industry
Collaborators
BIOTRONIK AG (A Teleflex Company)
First posted
Jan 16, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess the safety and efficacy of the Orsiro® Mission 48- mm Sirolimus-Eluting Coronary Stent System in the treatment of subjects with atherosclerotic lesion(s) \>36 mm and ≤ 44 mm in length (by visual estimate) in the native coronary arteries with a reference vessel diameter of 2.25 mm to 4.0 mm. Patients enrolled in the United States will be followed for 2 years post index procedure with follow-up visits at 1, 6, 12 months and 2 years post index procedure. Patients enrolled outside of the United States will be followed through 5 years post index procedure with additional follow-up visits at 3 and 5 years post index procedure.

Conditions

  • Coronary Artery Disease

Interventions

  • Orsiro Mission 48-mm Sirolimus-Eluting Coronary Stent SystemDevice

    Orsiro Mission is composed of a device (coronary stent system including a cobalt chromium stent platform) and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Target Lesion Failure (TLF) rate at 12 months post-index procedureTime frame: 12 months

Locations

23 sites in 6 countries. Site status is shown where the registry gives one.

  • John Muir Medical Center

    Concord, California · Recruiting

  • Ascension Via Christi Hospitals Wichita

    Wichita, Kansas · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

20 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.